{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:08:41Z","timestamp":1783908521252,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05254-4","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:31:13Z","timestamp":1775647873000},"page":"14029-14038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tofacitinib safety in inflammatory bowel disease: a disproportionality analysis of the FDA adverse event reporting system"],"prefix":"10.1007","volume":"399","author":[{"given":"Suqi","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sihan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"issue":"3","key":"5254_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/apt.14167","volume":"46","author":"A Amiot","year":"2017","unstructured":"Amiot A et al (2017) One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther 46(3):310\u2013321. https:\/\/doi.org\/10.1111\/apt.14167","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"5254_CR2","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1136\/ard-2022-222405","volume":"81","author":"A-R Balanescu","year":"2022","unstructured":"Balanescu A-R et al (2022) Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis 81(11):1491\u20131503. https:\/\/doi.org\/10.1136\/ard-2022-222405","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5254_CR3","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/apt.15689","volume":"51","author":"VBC Biemans","year":"2020","unstructured":"Biemans VBC et al (2020) Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. Aliment Pharmacol Ther 51(9):880\u2013888. https:\/\/doi.org\/10.1111\/apt.15689","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"5254_CR4","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41575-023-00758-3","volume":"20","author":"MN Brondfield","year":"2023","unstructured":"Brondfield MN, Mahadevan U (2023) Inflammatory bowel disease in pregnancy and breastfeeding. Nat Rev Gastroenterol Hepatol 20(8):504\u2013523. https:\/\/doi.org\/10.1038\/s41575-023-00758-3","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"5254_CR5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.86556","volume":"17","author":"M Burhanuddin","year":"2025","unstructured":"Burhanuddin M et al (2025) Efficacy and safety of tofacitinib in the management of ankylosing spondylitis: a comprehensive systematic review. Cureus 17(6):e86556. https:\/\/doi.org\/10.7759\/cureus.86556","journal-title":"Cureus"},{"key":"5254_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2505","volume":"357","author":"BL Cohen","year":"2017","unstructured":"Cohen BL, Sachar DB (2017) Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ 357:j2505. https:\/\/doi.org\/10.1136\/bmj.j2505","journal-title":"BMJ"},{"issue":"6","key":"5254_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R et al (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 367(6):495\u2013507. https:\/\/doi.org\/10.1056\/NEJMoa1109071","journal-title":"N Engl J Med"},{"issue":"10093","key":"5254_CR8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R et al (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390(10093):457\u2013468. https:\/\/doi.org\/10.1016\/S0140-6736(17)31618-5","journal-title":"Lancet"},{"issue":"4","key":"5254_CR9","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/ajg.2011.73","volume":"106","author":"AC Ford","year":"2011","unstructured":"Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P (2011) Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 106(4):644\u2013659. https:\/\/doi.org\/10.1038\/ajg.2011.73","journal-title":"Am J Gastroenterol"},{"key":"5254_CR10","doi-asserted-by":"publisher","unstructured":"Honap S et al. (2025) Janus Kinase (JAK) Inhibitor-induced acne in inflammatory bowel disease: an international, multicenter, retrospective cohort study. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc.\u00a0pp. S1542\u20133565(25)00465\u20133.\u00a0https:\/\/doi.org\/10.1016\/j.cgh.2025.04.031","DOI":"10.1016\/j.cgh.2025.04.031"},{"issue":"10","key":"5254_CR11","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s00108-022-01396-8","volume":"63","author":"J Kempski","year":"2022","unstructured":"Kempski J, Huber S (2022) [Role of the gut microbiome in the pathogenesis and treatment of inflammatory bowel diseases]. Inn. Med. Heidelb. Ger. 63(10):1022\u20131027. https:\/\/doi.org\/10.1007\/s00108-022-01396-8","journal-title":"Inn. Med. Heidelb. Ger."},{"issue":"2","key":"5254_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","volume":"155","author":"J Kirchgesner","year":"2018","unstructured":"Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R (2018) Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology 155(2):337-346.e10. https:\/\/doi.org\/10.1053\/j.gastro.2018.04.012","journal-title":"Gastroenterology"},{"issue":"5","key":"5254_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40273-023-01254-x","volume":"41","author":"T Kobayashi","year":"2023","unstructured":"Kobayashi T et al (2023) Cost-effectiveness analysis of tofacitinib compared with biologics in biologic-na\u00efve patients with moderate-to-severe ulcerative colitis in Japan. Pharmacoeconomics 41(5):589\u2013604. https:\/\/doi.org\/10.1007\/s40273-023-01254-x","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"5254_CR14","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s10067-025-07360-9","volume":"44","author":"B Mikaeili","year":"2025","unstructured":"Mikaeili B, Alqahtani ZA, Hincapie AL, Guo JJ (2025) Safety of Janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022. Clin Rheumatol 44(4):1467\u20131474. https:\/\/doi.org\/10.1007\/s10067-025-07360-9","journal-title":"Clin Rheumatol"},{"issue":"2","key":"5254_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/cod.14234","volume":"88","author":"A Muddebihal","year":"2023","unstructured":"Muddebihal A, Sardana K, Sinha S, Kumar D (2023) Tofacitinib in refractory Parthenium-induced airborne allergic contact dermatitis. Contact Dermatitis 88(2):150\u2013152. https:\/\/doi.org\/10.1111\/cod.14234","journal-title":"Contact Dermatitis"},{"issue":"10114","key":"5254_CR16","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","volume":"390","author":"SC Ng","year":"2017","unstructured":"Ng SC et al (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390(10114):2769\u20132778. https:\/\/doi.org\/10.1016\/S0140-6736(17)32448-0","journal-title":"Lancet"},{"issue":"10","key":"5254_CR17","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s40265-019-01141-w","volume":"79","author":"S Picardo","year":"2019","unstructured":"Picardo S, Seow CH (2019) A pharmacological approach to managing inflammatory bowel disease during conception, pregnancy and breastfeeding: biologic and oral small molecule therapy. Drugs 79(10):1053\u20131063. https:\/\/doi.org\/10.1007\/s40265-019-01141-w","journal-title":"Drugs"},{"issue":"7","key":"5254_CR18","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048","journal-title":"Int J Med Sci"},{"issue":"5","key":"5254_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMc1707500","volume":"377","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, Su C, Panes J (2017) Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 377(5):496\u2013497. https:\/\/doi.org\/10.1056\/NEJMc1707500","journal-title":"N Engl J Med"},{"issue":"5","key":"5254_CR20","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/ibd\/izae163","volume":"31","author":"M Shehab","year":"2025","unstructured":"Shehab M et al (2025) Comparative efficacy of biologics and small molecule therapies in improving patient-reported outcomes in ulcerative colitis: systematic review and network meta-analysis. Inflamm Bowel Dis 31(5):1272\u20131280. https:\/\/doi.org\/10.1093\/ibd\/izae163","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"5254_CR21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.5217\/ir.2020.00030","volume":"19","author":"H Shimizu","year":"2020","unstructured":"Shimizu H et al (2020) Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis. Intest Res 19(1):115\u2013118. https:\/\/doi.org\/10.5217\/ir.2020.00030","journal-title":"Intest Res"},{"issue":"45","key":"5254_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3238\/arztebl.m2023.0142","volume":"120","author":"A Stallmach","year":"2023","unstructured":"Stallmach A, Atreya R, Grunert PC, Stallhofer J, de Laffolie J, Schmidt C (2023) Treatment strategies in inflammatory bowel diseases. Dtsch Arztebl Int 120(45):768\u2013778. https:\/\/doi.org\/10.3238\/arztebl.m2023.0142","journal-title":"Dtsch Arztebl Int"},{"issue":"8","key":"5254_CR23","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","volume":"17","author":"C Steenholdt","year":"2023","unstructured":"Steenholdt C, Dige Ovesen P, Brynskov J, Seidelin JB (2023) Tofacitinib for acute severe ulcerative colitis: a systematic review. J Crohns Colitis 17(8):1354\u20131363. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad036","journal-title":"J Crohns Colitis"},{"issue":"1","key":"5254_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","volume":"17","author":"J Torres","year":"2023","unstructured":"Torres J et al (2023) European Crohn\u2019s and colitis guidelines on sexuality, fertility, pregnancy, and lactation. J Crohns Colitis 17(1):1\u201327. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac115","journal-title":"J Crohns Colitis"},{"issue":"10","key":"5254_CR25","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1093\/ibd\/izy131","volume":"24","author":"KL Winthrop","year":"2018","unstructured":"Winthrop KL et al (2018) Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis 24(10):2258\u20132265. https:\/\/doi.org\/10.1093\/ibd\/izy131","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"5254_CR26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/pds.3805","volume":"24","author":"CK Wong","year":"2015","unstructured":"Wong CK, Ho SS, Saini B, Hibbs DE, Fois RA (2015) Standardisation of the FAERS database: a systematic approach to manually recoding drug name variants. Pharmacoepidemiol Drug Saf 24(7):731\u2013737. https:\/\/doi.org\/10.1002\/pds.3805","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5254_CR27","doi-asserted-by":"publisher","unstructured":"Zeng\u00a0Y et al. (2025) Safety issues of tofacitinib in rheumatoid arthritis patients: real-world pharmacovigilance. Expert Opin. Drug Saf\u00a0 pp 1\u201315. https:\/\/doi.org\/10.1080\/14740338.2025.2527386","DOI":"10.1080\/14740338.2025.2527386"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05254-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05254-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05254-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:44:41Z","timestamp":1783907081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05254-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5254"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05254-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}